

ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

At the 2019 annual meeting of shareholders of ImmunoGen, Inc. held on June 20, 2019 (the “2019 Annual Meeting”), shareholders fixed the number of Directors constituting the full Board of Directors at seven. The voting results were as follows:

For:	91,726,038
Against	1,797,920
Abstain	1,649,411
Broker Non-Votes	37,812,197

At the 2019 Annual Meeting, shareholders elected seven Directors as follows:

	FOR	WITHHELD	BROKER NON-VOTES
Stephen C. McCluski	92,114,710	3,058,659	37,812,197
Richard J. Wallace	91,883,648	3,289,721	37,812,197
Mark Goldberg, MD	68,875,778	26,297,591	37,812,197
Dean J. Mitchell	83,207,216	11,966,153	37,812,197
Kristine Peterson	53,851,530	41,321,839	37,812,197
Mark J. Enyedy	92,766,242	2,407,127	37,812,197
Stuart A. Arbuckle	92,457,274	2,716,095	37,812,197

At the 2019 Annual Meeting, shareholders voted, on an advisory basis, against approval of the compensation paid to our named executive officers, as described in our proxy statement (the “say-on-pay vote”) as follows:

For:	8,972,438
Against	84,438,717
Abstain	1,762,214
Broker Non-Votes	37,812,197

At the 2019 Annual Meeting, shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2020 as follows:

For:	129,553,210
Against	1,237,073
Abstain	2,195,283
Broker Non-Votes	0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ImmunoGen, Inc.
(Registrant)

Date: June 24, 2019

/s/ Mark J. Enyedy

Mark J. Enyedy
President and Chief Executive Officer
